What is it about?

Rifampicin can cause P-gp induction- and inhibition-mediated DDIs with P-gp substrates in clinical. Our established PBPK model successfully predicted the P-gp-mediated DDIs and offered insights into P-gp induction levels in the intestine, liver, and kidney.

Featured Image

Why is it important?

Although the contribution of P-gp-mediated DDIs in the intestine, liver, and kidney was not clarified, our simulations have made it clear that the intestinal P-gp was impacted by rifampicin-mediated DDIs much more than hepatic or renal P-gp.

Perspectives

Our rifampicin PBPK model may enable net quantitative DDI predictions with various P-gp substrates that are in clinical use or under development.

Ryuta Asaumi
Astellas pharma Inc.

Read the Original

This page is a summary of: Robust PBPK Model of Rifampicin for Predicting Drug‐Drug Interactions via P‐gp Induction and Inhibition in Intestine, Liver, and Kidney, CPT Pharmacometrics & Systems Pharmacology, May 2022, Wiley, DOI: 10.1002/psp4.12807.
You can read the full text:

Read

Contributors

The following have contributed to this page